<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p94" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_94{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#t2_94{left:285px;bottom:827px;letter-spacing:-0.27px;}
#t3_94{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t4_94{left:341px;bottom:30px;}
#t5_94{left:348px;bottom:25px;letter-spacing:0.11px;}
#t6_94{left:377px;bottom:30px;}
#t7_94{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t8_94{left:540px;bottom:30px;}
#t9_94{left:546px;bottom:25px;letter-spacing:0.07px;}
#ta_94{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#tb_94{left:44px;bottom:63px;letter-spacing:0.1px;}
#tc_94{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_94{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_94{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_94{left:1123px;bottom:47px;letter-spacing:0.32px;}
#tg_94{left:1121px;bottom:28px;letter-spacing:0.19px;word-spacing:-0.15px;}
#th_94{left:36px;bottom:748px;letter-spacing:-0.11px;word-spacing:0.01px;}
#ti_94{left:36px;bottom:722px;letter-spacing:-0.09px;}
#tj_94{left:41px;bottom:704px;}
#tk_94{left:58px;bottom:704px;letter-spacing:-0.09px;}
#tl_94{left:58px;bottom:686px;letter-spacing:-0.09px;}
#tm_94{left:246px;bottom:686px;letter-spacing:-0.09px;}
#tn_94{left:360px;bottom:686px;}
#to_94{left:41px;bottom:667px;}
#tp_94{left:58px;bottom:667px;letter-spacing:-0.1px;word-spacing:0.01px;}
#tq_94{left:58px;bottom:649px;letter-spacing:-0.11px;word-spacing:0.02px;}
#tr_94{left:41px;bottom:631px;}
#ts_94{left:58px;bottom:631px;letter-spacing:-0.09px;}
#tt_94{left:58px;bottom:612px;letter-spacing:-0.1px;word-spacing:0.01px;}
#tu_94{left:58px;bottom:594px;letter-spacing:-0.1px;}
#tv_94{left:36px;bottom:562px;letter-spacing:-0.09px;}
#tw_94{left:41px;bottom:544px;}
#tx_94{left:58px;bottom:544px;letter-spacing:-0.1px;}
#ty_94{left:893px;bottom:551px;}
#tz_94{left:905px;bottom:544px;letter-spacing:-0.08px;}
#t10_94{left:58px;bottom:525px;letter-spacing:-0.1px;word-spacing:0.01px;}
#t11_94{left:58px;bottom:507px;letter-spacing:-0.1px;}
#t12_94{left:58px;bottom:489px;letter-spacing:-0.09px;}
#t13_94{left:41px;bottom:470px;}
#t14_94{left:58px;bottom:470px;letter-spacing:-0.09px;}
#t15_94{left:58px;bottom:452px;letter-spacing:-0.1px;}
#t16_94{left:41px;bottom:434px;}
#t17_94{left:58px;bottom:434px;letter-spacing:-0.09px;}
#t18_94{left:58px;bottom:415px;letter-spacing:-0.1px;word-spacing:0.01px;}
#t19_94{left:1029px;bottom:415px;letter-spacing:-0.11px;}
#t1a_94{left:58px;bottom:397px;letter-spacing:-0.1px;}
#t1b_94{left:364px;bottom:397px;}
#t1c_94{left:41px;bottom:379px;}
#t1d_94{left:58px;bottom:379px;letter-spacing:-0.12px;word-spacing:0.03px;}
#t1e_94{left:58px;bottom:360px;letter-spacing:-0.09px;}
#t1f_94{left:58px;bottom:342px;letter-spacing:-0.09px;}
#t1g_94{left:58px;bottom:324px;letter-spacing:-0.1px;word-spacing:0.01px;}
#t1h_94{left:58px;bottom:305px;letter-spacing:-0.14px;word-spacing:0.05px;}
#t1i_94{left:41px;bottom:287px;}
#t1j_94{left:58px;bottom:287px;letter-spacing:-0.09px;}
#t1k_94{left:58px;bottom:269px;letter-spacing:-0.11px;word-spacing:0.02px;}
#t1l_94{left:58px;bottom:250px;letter-spacing:-0.1px;}
#t1m_94{left:58px;bottom:232px;letter-spacing:-0.12px;word-spacing:0.03px;}
#t1n_94{left:41px;bottom:214px;}
#t1o_94{left:58px;bottom:214px;letter-spacing:-0.1px;}
#t1p_94{left:58px;bottom:195px;letter-spacing:-0.1px;word-spacing:0.01px;}
#t1q_94{left:1029px;bottom:203px;}
#t1r_94{left:1091px;bottom:108px;letter-spacing:-0.11px;}
#t1s_94{left:496px;bottom:778px;letter-spacing:0.44px;word-spacing:-0.26px;}
#t1t_94{left:36px;bottom:148px;}
#t1u_94{left:46px;bottom:142px;letter-spacing:0.12px;word-spacing:0.01px;}
#t1v_94{left:36px;bottom:131px;}
#t1w_94{left:46px;bottom:125px;letter-spacing:0.1px;word-spacing:-0.01px;}
#t1x_94{left:45px;bottom:108px;letter-spacing:0.14px;}
#t1y_94{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_94{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s1_94{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s2_94{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s3_94{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_94{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_94{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_94{font-size:17px;font-family:Webdings_k6;color:#000;}
.s7_94{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.s8_94{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.s9_94{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sa_94{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.sb_94{font-size:15px;font-family:ArialMT_k0;color:#000;}
.sc_94{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.sd_94{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts94" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

@font-face {
	font-family: Webdings_k6;
	src: url("fonts/Webdings_k6.woff") format("woff");
}

</style>
<div id="pg94Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg94" style="-webkit-user-select: none;"><object width="1210" height="935" data="94/94.svg" type="image/svg+xml" id="pdf94" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_94" class="t s0_94">NCCN Guidelines Version 4.2024 </span>
<span id="t2_94" class="t s0_94">Head and Neck Cancers </span>
<span id="t3_94" class="t s1_94">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t4_94" class="t s2_94">® </span>
<span id="t5_94" class="t s1_94">(NCCN </span>
<span id="t6_94" class="t s2_94">® </span>
<span id="t7_94" class="t s1_94">), All rights reserved. NCCN Guidelines </span>
<span id="t8_94" class="t s2_94">® </span>
<span id="t9_94" class="t s1_94">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="ta_94" class="t s3_94">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="tb_94" class="t s3_94">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="tc_94" class="t s4_94">NCCN Guidelines Index </span>
<span id="td_94" class="t s4_94">Table of Contents </span>
<span id="te_94" class="t s4_94">Discussion </span>
<span id="tf_94" class="t s5_94">IMG-A </span>
<span id="tg_94" class="t s5_94">2 OF 4 </span>
<span id="th_94" class="t s5_94">Initial Workup (continued) </span>
<span id="ti_94" class="t s5_94">• Nodal Metastases </span>
<span id="tj_94" class="t s6_94"></span><span id="tk_94" class="t s5_94">Evaluation of lymph node metastases should be conducted with CT or MRI of the neck, using whichever imaging study is suitable for </span>
<span id="tl_94" class="t s5_94">primary site evaluation </span><span id="tm_94" class="t s7_94">(IMG-A, 1 of 4)</span><span id="tn_94" class="t s5_94">. </span>
<span id="to_94" class="t s6_94"></span><span id="tp_94" class="t s5_94">For patients with multistation or lower neck nodal involvement or high-grade tumor histology, consider CT of the chest to assess for </span>
<span id="tq_94" class="t s5_94">mediastinal lymph node metastases or FDG-PET/CT, which is associated with higher sensitivity for both nodal and distant metastases. </span>
<span id="tr_94" class="t s6_94"></span><span id="ts_94" class="t s5_94">For patients who are under consideration for a surgical primary approach, the higher sensitivity of FDG-PET/CT is warranted for tumors </span>
<span id="tt_94" class="t s8_94" data-mappings='[[133,"fi"]]'>approaching the midline, to determine the surgical approach to the contralateral neck. Similarly, patients who are scheduled for a deﬁnitive </span>
<span id="tu_94" class="t s8_94" data-mappings='[[20,"fi"]]'>RT approach may beneﬁt from the higher sensitivity of FDG-PET/CT for identifying involved lymph nodes. </span>
<span id="tv_94" class="t s5_94">• Distant Metastases </span>
<span id="tw_94" class="t s6_94"></span><span id="tx_94" class="t s8_94">For patients with locoregionally advanced cancer (eg, T3–T4 primary or ≥N1 nodal staging), FDG-PET/CT </span>
<span id="ty_94" class="t s9_94">1 </span>
<span id="tz_94" class="t s5_94">is preferred to evaluate for </span>
<span id="t10_94" class="t s5_94">distant disease and thoracic metastases. However, FDG-PET/CT cannot rule out brain metastasis, and for cancers where this is a concern, </span>
<span id="t11_94" class="t s5_94">such as mucosal melanoma or high-grade neuroendocrine carcinomas or adenocarcinomas, contrast-enhanced brain MRI should be </span>
<span id="t12_94" class="t s5_94">additionally obtained. </span>
<span id="t13_94" class="t s6_94"></span><span id="t14_94" class="t s5_94">If FDG-PET/CT is not performed, CT of the chest should be performed to assess for presence of pulmonary metastases as well as </span>
<span id="t15_94" class="t s5_94">mediastinal lymph node involvement. </span>
<span id="t16_94" class="t s6_94"></span><span id="t17_94" class="t s8_94" data-mappings='[[38,"ffi"]]'>Non-contrast CT of the chest can be suﬃcient to screen for lung parenchymal metastases but is not adequate for assessment of </span>
<span id="t18_94" class="t s5_94">mediastinal adenopathy. This is an appropriate lung cancer screening intervention for patients with a history of smoking. </span><span id="t19_94" class="t s7_94">See NCCN </span>
<span id="t1a_94" class="t s7_94">Guidelines for Lung Cancer Screening</span><span id="t1b_94" class="t s5_94">. </span>
<span id="t1c_94" class="t s6_94"></span><span id="t1d_94" class="t s8_94" data-mappings='[[20,"fi"]]'>Following primary deﬁnitive treatment (surgery, RT, or systemic therapy/RT) the role of annual CT screening for lung metastasis is </span>
<span id="t1e_94" class="t s8_94" data-mappings='[[130,"ff"]]'>controversial. While this approach does detect early metastasis, further study is needed to determine the extent of the positive eﬀect and/ </span>
<span id="t1f_94" class="t s8_94" data-mappings='[[9,"ff"],[46,"fi"]]'>or cost-eﬀectiveness of this approach in speciﬁc subpopulations and timepoints post-treatment. For patients with a substantial smoking </span>
<span id="t1g_94" class="t s5_94">history or who are at high risk for lung metastases, annual chest CT can be considered. Historically, annual chest x-ray has been obtained </span>
<span id="t1h_94" class="t s5_94">but this is a much less sensitive test than CT. </span>
<span id="t1i_94" class="t s6_94"></span><span id="t1j_94" class="t s8_94" data-mappings='[[49,"fi"],[64,"fi"]]'>If clinical concern for metastatic disease is conﬁned to a speciﬁc anatomical area, the assessment of distant disease can be performed </span>
<span id="t1k_94" class="t s5_94">with directed CT or MRI examination. For example, pulmonary metastasis can be followed and assessed by non-contrast chest CT, or spinal </span>
<span id="t1l_94" class="t s8_94">metastasis can be followed and assessed by contrast-enhanced spine MRI. The frequency of such imaging tests depends on the planned </span>
<span id="t1m_94" class="t s5_94">treatment regimen and type of cancer. </span>
<span id="t1n_94" class="t s6_94"></span><span id="t1o_94" class="t s5_94">FDG-PET/CT may complement or replace other imaging modalities when staging recurrent disease before any therapy for relapsed/ </span>
<span id="t1p_94" class="t s8_94" data-mappings='[[89,"fi"]]'>refractory disease in order to explore distant disease or second primaries that may signiﬁcantly impact choice of therapy. </span>
<span id="t1q_94" class="t s9_94">2 </span>
<span id="t1r_94" class="t s7_94">Continued </span>
<span id="t1s_94" class="t s5_94">PRINCIPLES OF IMAGING </span>
<span id="t1t_94" class="t sa_94">1 </span>
<span id="t1u_94" class="t sb_94">PET/CT is preferred over PET scan alone (ie, without superimposed CT scan). PET/CT provides more accurate anatomical localization of abnormalities. </span>
<span id="t1v_94" class="t sa_94">2 </span>
<span id="t1w_94" class="t sc_94">Pantvaidya GH, Agarwal JP, Deshpande MS, et al. PET-CT in recurrent head neck cancers: a study to evaluate impact on patient management. J Surg </span>
<span id="t1x_94" class="t sc_94">Oncol 2009;100:401-403. </span>
<span id="t1y_94" class="t sd_94">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
